Log in
NASDAQ:DXCM

DexCom Competitors

$321.09
+5.22 (+1.65 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$314.63
Now: $321.09
$325.00
50-Day Range
$312.00
MA: $364.38
$418.00
52-Week Range
$182.07
Now: $321.09
$456.23
Volume1.30 million shs
Average Volume1.26 million shs
Market Capitalization$30.83 billion
P/E Ratio132.68
Dividend YieldN/A
Beta0.96

Competitors

DexCom (NASDAQ:DXCM) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying DXCM stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to DexCom, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

DexCom (NASDAQ:DXCM) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Risk & Volatility

DexCom has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Profitability

This table compares DexCom and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DexCom12.69%27.29%10.45%
Abbott Laboratories10.50%18.19%8.29%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for DexCom and Abbott Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DexCom141402.68
Abbott Laboratories141302.67

DexCom currently has a consensus price target of $406.2222, suggesting a potential upside of 26.51%. Abbott Laboratories has a consensus price target of $115.3750, suggesting a potential upside of 5.59%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts plainly believe DexCom is more favorable than Abbott Laboratories.

Valuation and Earnings

This table compares DexCom and Abbott Laboratories' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$1.48 billion20.89$101.10 million$1.84174.51
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

87.3% of DexCom shares are owned by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are owned by institutional investors. 0.7% of DexCom shares are owned by insiders. Comparatively, 1.7% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

DexCom beats Abbott Laboratories on 10 of the 14 factors compared between the two stocks.

DexCom (NASDAQ:DXCM) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Risk & Volatility

DexCom has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Profitability

This table compares DexCom and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DexCom12.69%27.29%10.45%
Medtronic15.80%10.47%5.80%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for DexCom and Medtronic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DexCom141402.68
Medtronic132012.84

DexCom currently has a consensus price target of $406.2222, suggesting a potential upside of 26.51%. Medtronic has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Given DexCom's higher probable upside, equities analysts plainly believe DexCom is more favorable than Medtronic.

Valuation and Earnings

This table compares DexCom and Medtronic's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$1.48 billion20.89$101.10 million$1.84174.51
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18

Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

87.3% of DexCom shares are owned by institutional investors. Comparatively, 79.9% of Medtronic shares are owned by institutional investors. 0.7% of DexCom shares are owned by insiders. Comparatively, 0.5% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

DexCom beats Medtronic on 8 of the 15 factors compared between the two stocks.

DexCom (NASDAQ:DXCM) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Risk & Volatility

DexCom has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Profitability

This table compares DexCom and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DexCom12.69%27.29%10.45%
Stryker11.38%20.53%8.89%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for DexCom and Stryker, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DexCom141402.68
Stryker291512.56

DexCom currently has a consensus price target of $406.2222, suggesting a potential upside of 26.51%. Stryker has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts plainly believe DexCom is more favorable than Stryker.

Valuation and Earnings

This table compares DexCom and Stryker's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$1.48 billion20.89$101.10 million$1.84174.51
Stryker$14.88 billion5.88$2.08 billion$8.2628.21

Stryker has higher revenue and earnings than DexCom. Stryker is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

87.3% of DexCom shares are owned by institutional investors. Comparatively, 71.0% of Stryker shares are owned by institutional investors. 0.7% of DexCom shares are owned by insiders. Comparatively, 6.8% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

DexCom beats Stryker on 9 of the 15 factors compared between the two stocks.

DexCom (NASDAQ:DXCM) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Valuation and Earnings

This table compares DexCom and Intuitive Surgical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$1.48 billion20.89$101.10 million$1.84174.51
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27

Intuitive Surgical has higher revenue and earnings than DexCom. Intuitive Surgical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DexCom and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DexCom12.69%27.29%10.45%
Intuitive Surgical24.45%12.08%10.44%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for DexCom and Intuitive Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DexCom141402.68
Intuitive Surgical371202.41

DexCom currently has a consensus price target of $406.2222, suggesting a potential upside of 26.51%. Intuitive Surgical has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts plainly believe DexCom is more favorable than Intuitive Surgical.

Risk & Volatility

DexCom has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Insider & Institutional Ownership

87.3% of DexCom shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 0.7% of DexCom shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

DexCom beats Intuitive Surgical on 8 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Valuation & Earnings

This table compares Becton, Dickinson and and DexCom's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40
DexCom$1.48 billion20.89$101.10 million$1.84174.51

Becton, Dickinson and has higher revenue and earnings than DexCom. Becton, Dickinson and is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Becton, Dickinson and and DexCom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
DexCom12.69%27.29%10.45%

Analyst Recommendations

This is a summary of recent ratings for Becton, Dickinson and and DexCom, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07712.60
DexCom141402.68

Becton, Dickinson and presently has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. DexCom has a consensus target price of $406.2222, suggesting a potential upside of 26.51%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Becton, Dickinson and.

Volatility and Risk

Becton, Dickinson and has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, DexCom has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Insider & Institutional Ownership

74.4% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 87.3% of DexCom shares are owned by institutional investors. 0.1% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 0.7% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

DexCom beats Becton, Dickinson and on 11 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Valuation & Earnings

This table compares Edwards Lifesciences and DexCom's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54
DexCom$1.48 billion20.89$101.10 million$1.84174.51

Edwards Lifesciences has higher revenue and earnings than DexCom. Edwards Lifesciences is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edwards Lifesciences and DexCom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
DexCom12.69%27.29%10.45%

Analyst Recommendations

This is a summary of recent ratings for Edwards Lifesciences and DexCom, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences251302.55
DexCom141402.68

Edwards Lifesciences presently has a consensus target price of $87.7222, suggesting a potential upside of 3.57%. DexCom has a consensus target price of $406.2222, suggesting a potential upside of 26.51%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Edwards Lifesciences.

Volatility and Risk

Edwards Lifesciences has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, DexCom has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Insider & Institutional Ownership

79.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 87.3% of DexCom shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 0.7% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


DexCom Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.